Business
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.
About this update from Q32 Bio Inc.
[{"type":"text","content":"-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 --","length":99,"tagName":"p","attribs":{}},{"type":"text","content":"-- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) --","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"-- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting --","length":237,"tagName":"p","attribs":{}},{"type":"text","content":"-- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 --","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.","length":354,"tagName":"p"},{"type":"text","content":""This past quarter brought exciting momentum for Q32 Bio and bempikibart as we received Fast Track designation, presented results as a late-breaking oral presentation at AAD, and advanced our SIGNAL-AA Phase 2a clinical trial, dosing the first patients in both Part B and the Part A OLE. These steps reflect our ongoing progress and commitment to developing bempikibart as a potential treatment for patients with alopecia areata who need new treatment options," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We look forward to sharing topline data from Part B in the first half of next year and continuing our efforts to advance bempikibart."","length":674,"tagName":"p"},{"type":"text","content":"First Quarter 2025 and Recent Business Highlights","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"FTD granted to bempikibart for the treatment of AA. Fast Track is a process designed to facilitate the development and expedite the review of new drugs to treat serious diseases and fill an unmet medical need with the purpose of getting important new drugs to patients earlier. Filling an un...